USRE39800E1 - Method for preventing restenosis using a substituted adenine derivative - Google Patents
Method for preventing restenosis using a substituted adenine derivative Download PDFInfo
- Publication number
- USRE39800E1 USRE39800E1 US10/780,553 US78055304A USRE39800E US RE39800 E1 USRE39800 E1 US RE39800E1 US 78055304 A US78055304 A US 78055304A US RE39800 E USRE39800 E US RE39800E
- Authority
- US
- United States
- Prior art keywords
- medicament
- recited
- procedure
- catheter procedure
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 76
- 208000037803 restenosis Diseases 0.000 title claims abstract description 32
- FCZOVUJWOBSMSS-UHFFFAOYSA-N 5-[(6-aminopurin-9-yl)methyl]-5-methyl-3-methylideneoxolan-2-one Chemical class C1=NC2=C(N)N=CN=C2N1CC1(C)CC(=C)C(=O)O1 FCZOVUJWOBSMSS-UHFFFAOYSA-N 0.000 title claims description 5
- 210000001616 monocyte Anatomy 0.000 claims abstract description 20
- 238000002513 implantation Methods 0.000 claims abstract description 5
- 230000003442 weekly effect Effects 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 35
- 238000002399 angioplasty Methods 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 210000005166 vasculature Anatomy 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 238000006303 photolysis reaction Methods 0.000 claims 1
- 230000015843 photosynthesis, light reaction Effects 0.000 claims 1
- 238000007674 radiofrequency ablation Methods 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 abstract description 29
- 238000011282 treatment Methods 0.000 abstract description 15
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 8
- 230000003902 lesion Effects 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract description 2
- 210000001367 artery Anatomy 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- FQQQYUSVPPBIGH-UHFFFAOYSA-N NC1=NC([Y])=NC2=C1N=CN2C1CC(O)C(CO)O1 Chemical compound NC1=NC([Y])=NC2=C1N=CN2C1CC(O)C(CO)O1 FQQQYUSVPPBIGH-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 201000009277 hairy cell leukemia Diseases 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 206010003162 Arterial injury Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 208000036490 Arterial inflammations Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010033174 Deoxycytidine kinase Proteins 0.000 description 1
- 102100029588 Deoxycytidine kinase Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
Definitions
- the present invention pertains generally to the prevention of atherosclerosis, its genesis, progression and restenosis following vascular repair. More specifically, the present invention pertains to the administration of a therapeutically effective dose of a substituted adenine derivative to prevent atherosclerosis, its genesis, progression and restenosis following vascular repair.
- the present invention is particularly, but not exclusively, useful for preventing a restenosis in human patients who have undergone a catheter based procedure, which may include a subsequent stent implantation, to dilate an arterial blockage in the patient's vasculature.
- Arteriosclerosis the group of diseases characterized by plaque deposition and gradual blockage of blood flow in arterial vessels, may result in ischemia of the heart, brain or extremities, resulting in infarction and sometimes death.
- Over 2,000,000 vascular interventions are performed each year worldwide with over 800,000 of these being performed in the United States.
- blocked arteries have been treated using a balloon catheter.
- This procedure known as percutaneous transluminal angioplasty (PTA)
- PTA percutaneous transluminal angioplasty
- Another catheter procedure commonly known as atherectomy, opens a blocked artery by grinding or cutting plaque deposits and suctioning the deposits from the artery.
- metal structures called stents have been placed in the affected artery to keep the previously blocked artery open after PTA or atherectomy treatment.
- stents have been placed in the affected artery to keep the previously blocked artery open after PTA or atherectomy treatment.
- Presently, over 70% of persons currently treated for arterial lesions have implanted stents.
- restenosis renarrowing of the opened artery.
- restenosis occurs in about 30% to 50% of patients.
- another PTA or atherectomy treatment is performed, and another stent is implanted, or bypass surgery is performed.
- restenosis occurs in about 60% of patients, who then must undergo yet another catheter procedure or submit to bypass surgery.
- 2-chloro-deoxyadenosine (2-CdA) is selectively toxic to monocytes, and is effective in lowering monocyte levels in humans.
- this medication (2-CdA) has been FDA approved for use in the treatment of hairy cell leukemia, and also has activity in cutaneous T-cell lymphoma, myeloid leukemias, chronic lymphocytic leukemia, Langerhans cell histiocytosis and non-Hodgkin's lymphoma. Additionally, FDA approval has been sought for treatment of multiple sclerosis.
- the present invention discloses a method of preventing restenosis by administering a therapeutically effective dose of 2-CdA.
- an object of the present invention to provide a method for preventing a restenosis in the vasculature of a patient which promotes a systemic suppression to the inflammation response that provokes a restenosis.
- Another object of the present invention is to provide a method for preventing a restenosis in the vasculature of a patient which uses a medication that can be administered orally, subcutaneously, intravenously, intramuscularly, or topically.
- Yet another object of the present invention is to provide a method for preventing restenosis in the vasculature of a patient which minimizes adverse side effects and, thus, is minimally intrusive into a patient's life style and quality of life.
- It is still another object of the present invention to provide a method for preventing a restenosis in the vasculature of a patient which uses a medication that is relatively easy to administer, is effective for its intended purpose, and is comparatively cost effective.
- the present invention discloses a method of treatment for progression of atherosclerosis and the prevention of restenosis in human patients who have submitted to catheter procedures, such as PTA or atherectomy, and who may subsequently require stent implantation in the area of an arterial lesion.
- the compound which is utilized as the active agent in the treatment is a 2-halo-2′-deoxyadenosine, which has a structure that corresponds to that of formula: Wherein Y is a halogen, either fluoro, chloro or bromo, but preferably chloro. When Y is chloro, the compound is 2-chloro-deoxyadenosine (2-CdA).
- restenosis is caused by the body's response to the inflammation that is associated with PTA and stent implantation.
- monocytes are generated and migrate in the blood to the damaged area of the artery.
- the monocytes differentiate into macrophages which, in turn, secrete cytokines and growth factors resulting in the migration and proliferation of the smooth muscle cells that contribute to a restenosis.
- Administration of 2-CdA is known to kill monocytes and hence lower the monocyte level in humans. In accordance with the present invention, this result is used for the specific purpose of suppressing or preventing a restenosis.
- One embodiment of the method of this invention includes the administration of 14 doses of 2-CdA in equal dosages of 0.12 mg/kg of body weight. Prior to the procedure used to obviate the arterial lesion, such as (PTA), the first dose is given. The remaining 12 equivalent doses are given thereafter at weekly intervals.
- PTA the procedure used to obviate the arterial lesion
- a particular advantage of the present invention is the convenient dosing regimen. Further, as intended for the present invention, dosages can be given either orally in a pill form, intravenously, subcutaneously or intramuscularly with injections, or topically, such as with the use of a carrier. In this aspect, a stent may be used as a carrier. Another advantage of the present invention is that 2-CdA has been FDA approved for the treatment of hairy cell leukemia, thus confirming a substantial safety profile for its use in human patients.
- monocytes which are immune cells derived from the bone marrow, migrate to the area of arterial injury, where they differentiate into tissue macrophages and secrete cytokines and growth factors. These cytokines and growth factors then result in restenosis by causing the above normal migration and proliferation of smooth muscle cells into the area. Also, once stimulated, the macrophages secrete a variety of mitogens which stimulate the transformation of smooth muscle cells from their normal contractile state to a secretory state. Further, the macrophages are scavenger cells that can absorb lipids and attack neighboring cells. The net result is an exuberant growth of tissue which encroaches the vessel lumen resulting in restenosis.
- monocytes In addition to initiating restenosis, monocytes have been implicated in every stage of atherosclerosis from the earliest fatty streaks found in children to the advanced fibromuscular lesions characterized by lipid-laden macrophages, smooth muscle cells, cholesterol crystals, and a fibrous cap. Macrophages are also believed to secrete enzymes called matrix metalloproteinases which lead to thinning and eventual rupture of the fibrous cap causing thrombosis of the coronary artery. Hence, one skilled in the art would recognize that the treatment method disclosed by the present invention may be applicable to every stage of atherosclerosis, and not merely to the prevention of restenosis.
- 2-chloro-deoxyadenosine (LEUSTATIN®, Cladribine, or 2-CdA) is a potent immunosuppressant selectively toxic to monocytes and lymphocytes, and is effective in lowering the monocyte levels in humans.
- 2-CdA causes cell death in monocytes. This mechanism proceeds as follows: 2-CdA in the bloodstream enters the lymphocyte cell, passively crossing the cell membrane. Once inside the lymphocyte cell, 2-CdA is phosphorylated by the lymphocyte enzyme deoxycytidine kinase.
- the 2-CdA can accumulate in the lymphocyte cell because it is resistant to deamination by adenosine deaminase. Phosphorylated 2-CdA is toxic to lymphocytes by causing impaired DNA synthesis and repair resulting in impaired RNA and protein synthesis and, ultimately, apoptosis or cell death.
- 2-CdA This medication, 2-CdA, has been FDA approved for use in the treatment of hairy cell leukemia, and has activity in cutaneous T-cell lymphoma, myeloid leukemias, chronic lymphocytic leukemia, langerhans cell histiocytosis and non-Hodgkin's lymphoma. Further, FDA approval has been sought for the use of 2-CdA in the treatment of multiple sclerosis. Use of 2-CdA in the above listed treatments has generated a favorable safety profile for use in humans.
- the present invention discloses a method of preventing atherosclerosis, its genesis, progression and restenosis by administering a therapeutically effective dose of 2-CdA to temporarily lower the monocyte level in the blood and specifically near the area of arterial inflammation. Lowering the monocyte level for a three month period following coronary intervention is preferred.
- One embodiment of the method of the present invention includes the administration of 14 doses of 2-CdA in a pharmacologically acceptable carrier or a pharmacologically acceptable acid addition salt of 2-CdA to the patient.
- an exemplary therapeutic dosage of 0.12 mg/kg of body weight is given prior to the catheter procedure used to obviate the arterial lesion.
- An equivalent second dose is given one day subsequent to the procedure, and the remaining 12 equivalent doses are given thereafter at weekly intervals.
- the 2-CdA could be administered in several ways including orally, topically, subcutaneously, intravenously or intramuscularly, it is practical to administer the first two dosages intravenously since the recipient is generally a hospital patient when the dosage is required, while the remaining dosages are given subcutaneously by medical personnel at outpatient clinics or in the home.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a method for the prevention of atherosclerosis, its genesis, progression and restenosis in human patients undergoing treatments for arterial lesions such as PTA or atherectomy, and which may be accompanied by stent implantation. Further, the treatment method disclosed has applicability in all stages of atherosclerosis in which monocytes play a role. The compound utilized in the present method as the active agent is a 2-halo-2′-deoxyadenosine such as 2-chloro-deoxyadenosine (2-CdA). The treatment method of the present invention includes the administration of 14 doses of 2-CdA in the amount of 0.12 mg/kg. One dose is given intravenously before the coronary intervention, another is given intravenously after the intervention and the remaining twelve doses are given subcutaneously at weekly intervals over a subsequent three month period.
Description
The present invention pertains generally to the prevention of atherosclerosis, its genesis, progression and restenosis following vascular repair. More specifically, the present invention pertains to the administration of a therapeutically effective dose of a substituted adenine derivative to prevent atherosclerosis, its genesis, progression and restenosis following vascular repair. The present invention is particularly, but not exclusively, useful for preventing a restenosis in human patients who have undergone a catheter based procedure, which may include a subsequent stent implantation, to dilate an arterial blockage in the patient's vasculature.
Arteriosclerosis, the group of diseases characterized by plaque deposition and gradual blockage of blood flow in arterial vessels, may result in ischemia of the heart, brain or extremities, resulting in infarction and sometimes death. Over 2,000,000 vascular interventions are performed each year worldwide with over 800,000 of these being performed in the United States. Since about 1977, blocked arteries have been treated using a balloon catheter. This procedure, known as percutaneous transluminal angioplasty (PTA), involves the insertion of a catheter into the lumen of a blocked artery and the inflation of an attached balloon to open the artery (both coronary and non-coronary vessels). Another catheter procedure, commonly known as atherectomy, opens a blocked artery by grinding or cutting plaque deposits and suctioning the deposits from the artery. More recently, metal structures called stents have been placed in the affected artery to keep the previously blocked artery open after PTA or atherectomy treatment. Presently, over 70% of persons currently treated for arterial lesions have implanted stents.
It is fortunate that over 90% of coronary interventions are successful in opening the blocked artery. However, the later renarrowing of the opened artery, (i.e. restenosis) remains a significant problem. Unfortunately, within six months after a first PTA or atherectomy treatment, restenosis occurs in about 30% to 50% of patients. When restenosis occurs, either another PTA or atherectomy treatment is performed, and another stent is implanted, or bypass surgery is performed. After a second catheter procedure, restenosis occurs in about 60% of patients, who then must undergo yet another catheter procedure or submit to bypass surgery.
Though many details of restenosis remain unclear, the general consensus is that angioplasty and stenting, either individually or collectively, cause a stretch and tear injury to the arterial wall which results in an inflammation that leads to the activation of multiple cell lines. In particular, there is concern for the monocyte/macrophage line. Specifically, it is known that monocytes will migrate to the area of an arterial injury. There, they are differentiate into tissue macrophages and secrete cytokines and growth factors which cause the migration and proliferation of smooth muscle cells into the area. This results in excessive tissue growth or restenosis.
Not surprisingly, efforts have been taken to prevent restenosis. For example, medications such as calcium channel blockers, corticosteroids, antiplatelet agents, fish oils, lovastatin and anticoagulants have been tried in attempts to prevent restenosis. Heretofore, however, these efforts have been generally unsuccessful. Radiation therapy has been shown to reduce restenosis, but radiation therapy is generally impractical because it is time consuming, requires specialized equipment, specialized personnel, and is often difficult to arrange. Some immunosuppressants, on the other hand, show promise.
It is known that the immunosuppressant medication 2-chloro-deoxyadenosine (2-CdA) is selectively toxic to monocytes, and is effective in lowering monocyte levels in humans. Presently, this medication (2-CdA) has been FDA approved for use in the treatment of hairy cell leukemia, and also has activity in cutaneous T-cell lymphoma, myeloid leukemias, chronic lymphocytic leukemia, Langerhans cell histiocytosis and non-Hodgkin's lymphoma. Additionally, FDA approval has been sought for treatment of multiple sclerosis. As a new and useful application, the present invention discloses a method of preventing restenosis by administering a therapeutically effective dose of 2-CdA.
In light of the above, it is an object of the present invention to provide a method for preventing a restenosis in the vasculature of a patient which promotes a systemic suppression to the inflammation response that provokes a restenosis. Another object of the present invention is to provide a method for preventing a restenosis in the vasculature of a patient which uses a medication that can be administered orally, subcutaneously, intravenously, intramuscularly, or topically. Yet another object of the present invention is to provide a method for preventing restenosis in the vasculature of a patient which minimizes adverse side effects and, thus, is minimally intrusive into a patient's life style and quality of life. It is still another object of the present invention to provide a method for preventing a restenosis in the vasculature of a patient which uses a medication that is relatively easy to administer, is effective for its intended purpose, and is comparatively cost effective.
The present invention discloses a method of treatment for progression of atherosclerosis and the prevention of restenosis in human patients who have submitted to catheter procedures, such as PTA or atherectomy, and who may subsequently require stent implantation in the area of an arterial lesion. In accordance with the present invention, the compound which is utilized as the active agent in the treatment is a 2-halo-2′-deoxyadenosine, which has a structure that corresponds to that of formula:
Wherein Y is a halogen, either fluoro, chloro or bromo, but preferably chloro. When Y is chloro, the compound is 2-chloro-deoxyadenosine (2-CdA).
Wherein Y is a halogen, either fluoro, chloro or bromo, but preferably chloro. When Y is chloro, the compound is 2-chloro-deoxyadenosine (2-CdA).
There is general agreement that restenosis is caused by the body's response to the inflammation that is associated with PTA and stent implantation. In this response, monocytes are generated and migrate in the blood to the damaged area of the artery. Once there, the monocytes differentiate into macrophages which, in turn, secrete cytokines and growth factors resulting in the migration and proliferation of the smooth muscle cells that contribute to a restenosis. Administration of 2-CdA, however, is known to kill monocytes and hence lower the monocyte level in humans. In accordance with the present invention, this result is used for the specific purpose of suppressing or preventing a restenosis.
One embodiment of the method of this invention includes the administration of 14 doses of 2-CdA in equal dosages of 0.12 mg/kg of body weight. Prior to the procedure used to obviate the arterial lesion, such as (PTA), the first dose is given. The remaining 12 equivalent doses are given thereafter at weekly intervals.
A particular advantage of the present invention is the convenient dosing regimen. Further, as intended for the present invention, dosages can be given either orally in a pill form, intravenously, subcutaneously or intramuscularly with injections, or topically, such as with the use of a carrier. In this aspect, a stent may be used as a carrier. Another advantage of the present invention is that 2-CdA has been FDA approved for the treatment of hairy cell leukemia, thus confirming a substantial safety profile for its use in human patients.
As mentioned above, there is general agreement that catheter procedures such as angioplasty, atherectomy and/or stenting causes a stretch and tear injury to the arterial wall which causes an inflammation. This inflammation leads to the activation of multiple cell lines, and in particular, the monocyte/macrophage line. Monocytes, which are immune cells derived from the bone marrow, migrate to the area of arterial injury, where they differentiate into tissue macrophages and secrete cytokines and growth factors. These cytokines and growth factors then result in restenosis by causing the above normal migration and proliferation of smooth muscle cells into the area. Also, once stimulated, the macrophages secrete a variety of mitogens which stimulate the transformation of smooth muscle cells from their normal contractile state to a secretory state. Further, the macrophages are scavenger cells that can absorb lipids and attack neighboring cells. The net result is an exuberant growth of tissue which encroaches the vessel lumen resulting in restenosis.
In addition to initiating restenosis, monocytes have been implicated in every stage of atherosclerosis from the earliest fatty streaks found in children to the advanced fibromuscular lesions characterized by lipid-laden macrophages, smooth muscle cells, cholesterol crystals, and a fibrous cap. Macrophages are also believed to secrete enzymes called matrix metalloproteinases which lead to thinning and eventual rupture of the fibrous cap causing thrombosis of the coronary artery. Hence, one skilled in the art would recognize that the treatment method disclosed by the present invention may be applicable to every stage of atherosclerosis, and not merely to the prevention of restenosis.
The medication 2-chloro-deoxyadenosine (LEUSTATIN®, Cladribine, or 2-CdA) is a potent immunosuppressant selectively toxic to monocytes and lymphocytes, and is effective in lowering the monocyte levels in humans. Although the exact mechanism by which 2-CdA causes cell death in monocytes is unknown, a mechanism has been established whereby 2-CdA causes cell death in lymphocytes. This mechanism proceeds as follows: 2-CdA in the bloodstream enters the lymphocyte cell, passively crossing the cell membrane. Once inside the lymphocyte cell, 2-CdA is phosphorylated by the lymphocyte enzyme deoxycytidine kinase. Once phosphorylated, the 2-CdA can accumulate in the lymphocyte cell because it is resistant to deamination by adenosine deaminase. Phosphorylated 2-CdA is toxic to lymphocytes by causing impaired DNA synthesis and repair resulting in impaired RNA and protein synthesis and, ultimately, apoptosis or cell death.
This medication, 2-CdA, has been FDA approved for use in the treatment of hairy cell leukemia, and has activity in cutaneous T-cell lymphoma, myeloid leukemias, chronic lymphocytic leukemia, langerhans cell histiocytosis and non-Hodgkin's lymphoma. Further, FDA approval has been sought for the use of 2-CdA in the treatment of multiple sclerosis. Use of 2-CdA in the above listed treatments has generated a favorable safety profile for use in humans.
Hence, the present invention discloses a method of preventing atherosclerosis, its genesis, progression and restenosis by administering a therapeutically effective dose of 2-CdA to temporarily lower the monocyte level in the blood and specifically near the area of arterial inflammation. Lowering the monocyte level for a three month period following coronary intervention is preferred.
One embodiment of the method of the present invention includes the administration of 14 doses of 2-CdA in a pharmacologically acceptable carrier or a pharmacologically acceptable acid addition salt of 2-CdA to the patient. As summarized in the following table, an exemplary therapeutic dosage of 0.12 mg/kg of body weight is given prior to the catheter procedure used to obviate the arterial lesion. An equivalent second dose is given one day subsequent to the procedure, and the remaining 12 equivalent doses are given thereafter at weekly intervals.
| Dose (mg/kg of | Method of | |
| body weight) | Administration | Time of Administration |
| 0.12 | Intravenously | Prior to Catheter Procedure |
| 0.12 | Intravenously | Day After Catheter Procedure |
| 0.12 | Subcutaneously | One week after Catheter Procedure |
| 0.12 | Subcutaneously | Two weeks after Catheter Procedure |
| 0.12 | Subcutaneously | Three weeks after Catheter Procedure |
| 0.12 | Subcutaneously | Four weeks after Catheter Procedure |
| 0.12 | Subcutaneously | Five weeks after Catheter Procedure |
| 0.12 | Subcutaneously | Six weeks after Catheter Procedure |
| 0.12 | Subcutaneously | Seven weeks after Catheter Procedure |
| 0.12 | Subcutaneously | Eight weeks after Catheter Procedure |
| 0.12 | Subcutaneously | Nine weeks after Catheter Procedure |
| 0.12 | Subcutaneously | Ten weeks after Catheter Procedure |
| 0.12 | Subcutaneously | Eleven weeks after Catheter Procedure |
| 0.12 | Subcutaneously | Twelve weeks after Catheter Procedure |
Although the 2-CdA could be administered in several ways including orally, topically, subcutaneously, intravenously or intramuscularly, it is practical to administer the first two dosages intravenously since the recipient is generally a hospital patient when the dosage is required, while the remaining dosages are given subcutaneously by medical personnel at outpatient clinics or in the home.
While the particular method as herein disclosed in detail is fully capable of obtaining the objects and providing the advantages herein before stated, it is to be understood that it is merely illustrative of the presently preferred embodiments of the invention and that no limitations are intended to the details of construction or design here in shown other than as described in the appended claims.
Claims (18)
1. A method for preventing a restenosis at a location of an inflammation in the vasculature of a patient which comprises the steps of:
apportioning a medicament into a plurality of therapeutically effective doses, wherein said medicament is selected from a group consisting of a substituted adenine derivative and a pharmacologically acceptable acid addition salt thereof, said medicament having the formula:
wherein Y is a halogen, each said dose of said medicament being efficacious for responding to said inflammation by reducing monocytes in the blood to below a preselected level; and
administering at least one of said doses to a human in accordance with a predetermined regimen.
2. The method as recited in claim 1 wherein Y is chlonine chlorine.
3. The method as recited in claim 1 wherein said inflammation results from a catheter procedure.
4. The method as recited in claim 3 wherein said catheter procedure is a percutaneous transluminal angioplasty (PTA) procedure.
5. The method as recited in claim 3 wherein said catheter procedure is selected from a group consisting of an atherectomy procedure, a photolysis procedure and a radio frequency ablation procedure.
6. The method as recited in claim 3 wherein said catheter procedure includes implantation of an arterial stent.
7. The method as recited in claim 1 wherein said predetermined regime comprises the step of:
preparing fourteen individual portions of said medicament;
administering a first said portion of said medicament to said human prior to a catheter procedure;
administering a second said portion of said medicament to said human subsequent said catheter procedure; and
administering one of said remaining twelve portions of said medicament at consecutive weekly intervals over a twelve week period immediately following said administering of said second said portion of said medicament.
8. The method as recited in claim 7 wherein said first portion of said medicament is administered on the day of said catheter procedure and said second portion of said medicament is administered on the day immediately following said catheter procedure.
9. The method as recited in claim 7 wherein each said portion of said medicament is approximately one twelve hundredths of a milligram per kilogram of body weight (0.12 mg/Kg).
10. The method as recited in claim 7 wherein said first and second portions of said medicament are administered intravenously, and said remaining portions are administered subcutaneously.
11. A method for reducing the production of monocytes in a patient to prevent a restenosis wherein said method comprises the steps of:
preparing fourteen individual portions of a medicament, wherein said medicament is selected from a group consisting of a substituted adenine derivative and a pharmacologically acceptable acid addition salt thereof, said medicament having the formula:
wherein Y is a halogen;
administering a first said portion of said medicament to said human prior to a catheter procedure;
providing a second said portion of said medicament to said human subsequent said catheter procedure; and
dispensing one of said remaining twelve portions of said medicament at consecutive weekly intervals over a twelve week period immediately following said administering of said second said portion of said medicament.
12. The method as recited in claim 11 wherein said first portion of said medicament is administered on the day of said catheter procedure and said second portion of said medicament is administered on the day immediately following said catheter procedure.
13. The method as recited in claim 11 wherein each said portion of said medicament is approximately one twelve hundredths of a milligram per kilogram of body weight (0.12 mg/Kg).
14. The method as recited in claim 11 wherein said first and second portions of said medicament are administered intravenously, and said remaining portions are administered subcutaneously.
15. The method as recited in claim 11 wherein Y is chlorine.
16. A method for preventing a restenosis at a location of an inflammation in the vasculature of a patient which comprises the steps of:
apportioning a medicament into a plurality of therapeutically effective doses, wherein said medicament is selected from a group consisting of a substituted adenine derivative and a pharmacologically acceptable acid addition salt thereof, said medicament having the formula: 
wherein Y is a halogen, each said dose of said medicament being efficacious for responding to said inflammation by reducing monocytes in the blood to below a preselected level; and
administering at least one of said doses to a human topically with a carrier in accordance with a predetermined regimen.
17. The method as recited in claim 16 wherein said carrier is a stent.
18. The method as recited in claim 16 wherein Y is chlorine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/780,553 USRE39800E1 (en) | 1999-10-05 | 2004-02-18 | Method for preventing restenosis using a substituted adenine derivative |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/412,418 US6239118B1 (en) | 1999-10-05 | 1999-10-05 | Method for preventing restenosis using a substituted adenine derivative |
| US10/780,553 USRE39800E1 (en) | 1999-10-05 | 2004-02-18 | Method for preventing restenosis using a substituted adenine derivative |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/412,418 Reissue US6239118B1 (en) | 1999-10-05 | 1999-10-05 | Method for preventing restenosis using a substituted adenine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| USRE39800E1 true USRE39800E1 (en) | 2007-08-28 |
Family
ID=23632883
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/412,418 Ceased US6239118B1 (en) | 1999-10-05 | 1999-10-05 | Method for preventing restenosis using a substituted adenine derivative |
| US10/780,553 Expired - Lifetime USRE39800E1 (en) | 1999-10-05 | 2004-02-18 | Method for preventing restenosis using a substituted adenine derivative |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/412,418 Ceased US6239118B1 (en) | 1999-10-05 | 1999-10-05 | Method for preventing restenosis using a substituted adenine derivative |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US6239118B1 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6241762B1 (en) | 1998-03-30 | 2001-06-05 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
| US7208011B2 (en) | 2001-08-20 | 2007-04-24 | Conor Medsystems, Inc. | Implantable medical device with drug filled holes |
| US20040254635A1 (en) * | 1998-03-30 | 2004-12-16 | Shanley John F. | Expandable medical device for delivery of beneficial agent |
| US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
| US6767544B2 (en) * | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
| US20060216313A1 (en) * | 1999-08-10 | 2006-09-28 | Allergan, Inc. | Methods for treating a stricture with a botulinum toxin |
| AU780539B2 (en) * | 2000-02-25 | 2005-03-24 | Cordis Corporation | Use of cladribine on a stent to prevent restenosis |
| EP1498084B1 (en) | 2000-10-16 | 2014-06-18 | Innovational Holdings, LLC | Expandable medical device for delivery of beneficial agent |
| US20040204756A1 (en) * | 2004-02-11 | 2004-10-14 | Diaz Stephen Hunter | Absorbent article with improved liquid acquisition capacity |
| US20040249443A1 (en) * | 2001-08-20 | 2004-12-09 | Shanley John F. | Expandable medical device for treating cardiac arrhythmias |
| US7056338B2 (en) | 2003-03-28 | 2006-06-06 | Conor Medsystems, Inc. | Therapeutic agent delivery device with controlled therapeutic agent release rates |
| DE10162480A1 (en) * | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | The application of mRNA for use as a therapeutic agent against tumor diseases |
| AU2003287633A1 (en) * | 2002-11-08 | 2004-06-03 | Innovational Holdings, Llc | Method and apparatus for reducing tissue damage after ischemic injury |
| US20040142014A1 (en) * | 2002-11-08 | 2004-07-22 | Conor Medsystems, Inc. | Method and apparatus for reducing tissue damage after ischemic injury |
| US7704125B2 (en) | 2003-03-24 | 2010-04-27 | Nexplanar Corporation | Customized polishing pads for CMP and methods of fabrication and use thereof |
| US9278424B2 (en) | 2003-03-25 | 2016-03-08 | Nexplanar Corporation | Customized polishing pads for CMP and methods of fabrication and use thereof |
| US8864859B2 (en) | 2003-03-25 | 2014-10-21 | Nexplanar Corporation | Customized polishing pads for CMP and methods of fabrication and use thereof |
| AU2004226327A1 (en) | 2003-03-28 | 2004-10-14 | Innovational Holdings, Llc | Implantable medical device with beneficial agent concentration gradient |
| DK2272503T3 (en) * | 2003-03-28 | 2013-05-21 | Ares Trading Sa | Oral formulations of cladribine |
| US20050010170A1 (en) * | 2004-02-11 | 2005-01-13 | Shanley John F | Implantable medical device with beneficial agent concentration gradient |
| AU2004226435B2 (en) * | 2003-03-28 | 2009-11-12 | Ares Trading S.A. | Cladribine formulations for improved oral and transmucosal delivery |
| UA81305C2 (en) | 2003-07-02 | 2007-12-25 | Ares Trading Sa | Formulation of cladribine (variants), cladribine-cyclodextrin complex, use of cladribine-cyclodextrin complex, mixture |
| US20050100577A1 (en) * | 2003-11-10 | 2005-05-12 | Parker Theodore L. | Expandable medical device with beneficial agent matrix formed by a multi solvent system |
| US20050287287A1 (en) * | 2004-06-24 | 2005-12-29 | Parker Theodore L | Methods and systems for loading an implantable medical device with beneficial agent |
| USD516723S1 (en) | 2004-07-06 | 2006-03-07 | Conor Medsystems, Inc. | Stent wall structure |
| TWI385050B (en) * | 2005-02-18 | 2013-02-11 | Nexplanar Corp | Customized polishing pads for cmp and methods of fabrication and use thereof |
| US8845627B2 (en) | 2008-08-22 | 2014-09-30 | Boston Scientific Scimed, Inc. | Regulating pressure to lower temperature in a cryotherapy balloon catheter |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106837A (en) * | 1988-03-16 | 1992-04-21 | The Scripps Research Institute | Adenosine derivatives with therapeutic activity |
| US5424296A (en) * | 1993-04-15 | 1995-06-13 | The Scripps Research Institute | 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma |
| US5510336A (en) * | 1994-09-06 | 1996-04-23 | Saven; Alan | 2-halo-2'-deoxyadenosine treatment for histiocytosis |
-
1999
- 1999-10-05 US US09/412,418 patent/US6239118B1/en not_active Ceased
-
2004
- 2004-02-18 US US10/780,553 patent/USRE39800E1/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106837A (en) * | 1988-03-16 | 1992-04-21 | The Scripps Research Institute | Adenosine derivatives with therapeutic activity |
| US5424296A (en) * | 1993-04-15 | 1995-06-13 | The Scripps Research Institute | 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma |
| US5510336A (en) * | 1994-09-06 | 1996-04-23 | Saven; Alan | 2-halo-2'-deoxyadenosine treatment for histiocytosis |
Non-Patent Citations (10)
| Title |
|---|
| Copy of Brochure for Leustatin.RTM. (cladribine) Injection; Ortho Biotech, Raritan, New Jersey, Dec. 1996. * |
| Faxon, David P., M.D., Chronic Inflamation, Clinical Trials and Remodeling; pp. 136-138; University of Southern California School of Medicine, Los Angeles, CA; Restenosis Summit VIII, 1996. * |
| Gerrity, Ross G., PhD. The Role of the Monocyte in Atherogenesis, pp. 181 and 191; Research Division, The Cleveland Clinic Foundation, Cleveland, Ohio, Nov. 1, 1980. * |
| Leibovich, S. J. PhD. et al., A Macrophage-Dependent Factor That Stimulates the Proliferation of Fibroblasts in Vitro; American Journal of Pathology; pp. 501, 508 and 511; Department of Pathology, University of Washington School of Medicine, Seattle, Washington, Apr. 23, 1976. * |
| Libby et al, Nouv Rev Fr Hematol, 34 Suppl. S47-53, 1992. * |
| Ross, Russell, PhD. Medical Progress; The Pathogenesis of Athersclerosis-An Update; The New England Journal of Medicine vol. 314, No. 8, pp. 488, 493, 494; Department of Patholology, University of Washington School of Medicine, Seattle, Washington; Feb. 20, 1986. * |
| Ross, Russell, PhD., Mechanism of Disease Atherosclerosis-An Inflammatory Disease, The New England Journal of Medicine vol. 340, No. 2, pp. 115-126; Department of Pathology, University of Washington School of Medicine, Seattle, Washington; Jan. 14, 1999. * |
| Saven, Alan, M.D., et al.; Brief Communications, 2-Chlorodeoxyadenosine-induced Complete Remissions in Langerhans-Cell Histiocytosis, pp. 430-432; Reprinted from Annals of Internal Medicine, vol. 121, No. 6, Sep. 15, 1994. * |
| Schwartz, Stephen M., et al; Remodeling: How Vessels Narrow, Clinical Trials and Remodeling; pp. 128-131; University of Washington, Seattle, WA; Massachusetts General Hospital, Boston, MA; and ZymoGenetics, Inc., Seattle WA, 1996. * |
| Waltenberger, Johannes, M.D., Current Perspectives, Modulation of Growth Factor Action, Implications for the Treatment of Cardiovascular Diseases; Circulation, pp. 4083-4094; vol. 96, No. 11, Department of Internal Medicine II (Cardiology); Ulm University Medical Center, Ulm, Germany; Dec. 2, 1997. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US6239118B1 (en) | 2001-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USRE39800E1 (en) | Method for preventing restenosis using a substituted adenine derivative | |
| Watt et al. | Intravenous adenosine in the treatment of supraventricular tachycardia: a dose‐ranging study and interaction with dipyridamole. | |
| US20090011005A1 (en) | Pharmaceuticals compositions containing nanomaterials useful for treating restenotic lesions | |
| JPH0840901A (en) | Medical composition for preventing excessively proliferativehemal disease | |
| WO1996012480A1 (en) | Polyamine compounds for treating vascular proliferative disorders | |
| Waksman et al. | Late thrombosis following intracoronary brachytherapy | |
| Morgan et al. | Central nervous system targeting of 2', 3'-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs | |
| CH683966A5 (en) | Compounds of the ftalidrazidici class as active substances in anti-hypoxic agents and defense. | |
| EP0363671A2 (en) | Use of ACE inhibitors against the formation of neo-intima after vascular infliction | |
| EP0305181A2 (en) | Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin | |
| RU2365380C1 (en) | Method of acute myocardial infarction treatment | |
| EP3701956B1 (en) | Prophylactic and/or therapeutic agent for dementia | |
| EP1190714A2 (en) | Method for the treatment of thromboembolic disorders in patients with aspirin resistance | |
| GB2270841A (en) | Compositions for Treating vascular restenosis | |
| Rich et al. | The angiographic effect of ergonovine and nifedipine in coronary artery spasm. | |
| Kim et al. | Successful percutaneous coronary intervention for acute coronary syndrome in a patient with severe hemophilia A | |
| JP2548491B2 (en) | Agent for the prevention and treatment of intimal thickening | |
| WO1999036074A1 (en) | Use of 8-cl-camp in prevention of restenosis of arterial walls | |
| Jamakovic et al. | Successful dilatation of underexpanded stent with super-high-pressure balloon: A case report | |
| AU721632B2 (en) | Agent for preventing restenosis | |
| JPH09227381A (en) | Improving agent for motor paralysis in cerebral thorombosis | |
| KR100987557B1 (en) | Compositions for treating or preventing vascular restenosis | |
| EP1796684A1 (en) | Vitamin b6 related compounds and methods for recovery from trauma | |
| Schweiger et al. | Distal coronary artery injury following successful percutaneous transluminal coronary angioplasty | |
| US6498152B1 (en) | Use of a farnesyl transferase inhibitor in the manufacture of a medicament for local administration to the vascular wall in the prevention of restenosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FEPP | Fee payment procedure |
Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| REFU | Refund |
Free format text: REFUND - PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: R2552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |